Express News | Quoin Pharmaceuticals Expands Netherton Syndrome Clinical Studies Internationally; First Site to Open in Saudi Arabia; Engages Experienced Local Clinical Research Organization; Plans for Additional Sites at Advanced Stage

BenzingaJun 27 08:05 ET

Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin StudiesExperienced Local Clinical Research Organization Has Been

Quoin PharmaceuticalsJun 27 00:00 ET

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan dis

Quoin PharmaceuticalsJun 25 00:00 ET

Maxim Group Maintains Quoin Pharmaceuticals(QNRX.US) With Buy Rating, Maintains Target Price $4

Maxim Group analyst Naz Rahman maintains $Quoin Pharmaceuticals(QNRX.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 27.6% an

moomoo NewsJun 13 11:32 ET · Ratings

Express News | Quoin Pharmaceuticals Signs Research Agreement With University College Cork Encompassing The Development Of Topical Formulations Of Rapamycin

BenzingaJun 12 08:10 ET

Quoin Pharmaceuticals Announces Signing of Research Agreement With University College Cork (UCC), Ireland

Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseasesUCC's proprietary dissolvable microneedles t

Quoin PharmaceuticalsJun 12 00:00 ET